Is Medigene AG halal to invest in?

As of August 2026, Medigene AG MDG2.VI is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Medigene AG a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Medigene AG using these criteria to determine its compliance status.

Can Muslims buy shares of Medigene AG?

Muslim investors may consider investing in Medigene AG if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Medigene AG classified as HALAL?

Musaffa determines the Shariah status of Medigene AG by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Medigene AG updated?

The Shariah compliance status of Medigene AG may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Medigene AG become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Medigene AG?

You can check the latest Shariah compliance status of Medigene AG on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Medigene AG MDG2.VI

Last Updated: Nov 18, 12:00 AM·WBAG

MDG2.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Medigene AG is classified as halal.

HALAL

Report Source: undefined Quarter Report

Medigene AG. Stock Analysis MDG2.VI

Austria Health Care Nano Cap

MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. The company employs 86 full-time employees The company went IPO on 2000-06-30. The firm focuses on the development of personalized T cell-based immunotherapies. The company develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The firm operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.